TakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses Potential for...

At nearly 28 months of median follow-up, median progression-free survival and overall survival were not yet reached Data presented at the 2022 ASCO Annual Meeting and published in the Journal of...

In the news release, Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly...

Chief People Officer Gina Cherwin to share her experience as an advocate for working parents and insights on returning to the office with a hybrid model NEW YORK, June 3, 2022 MikeWorldWide, a...

Today, during the U.S. Conference of Mayors' 90th Annual Meeting in Reno (NV), twelve mayors will be recognized for their efforts to address the climate crisis as part of the 2022 Mayors' Climate...